Cover Image
市場調查報告書

液態切片市場:全球市場規模、策略、預測

LIQUID BIOPSY MARKETS 2016 to 2020 - Global Market Size, Strategies and Forecasts including Screening Market Sizing

出版商 Howe Sound Research 商品編碼 333705
出版日期 內容資訊 英文 246 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
液態切片市場:全球市場規模、策略、預測 LIQUID BIOPSY MARKETS 2016 to 2020 - Global Market Size, Strategies and Forecasts including Screening Market Sizing
出版日期: 2016年10月07日 內容資訊: 英文 246 Pages
簡介

本報告提供全球液態切片市場相關調查、產業結構與主要的進入經營者、主要經營者的市場佔有率、推動市場成長的要素與阻礙要素分析、市場及技術的發展趨勢、近幾年的企業及企業間的配合措施、各地區/國家、檢驗種類的市場規模的變化與預測等彙整資料。

第1章 簡介、市場定義

第2章 市場概要

  • 市場參與企業
  • 切片檢查識別的疾病
  • 切片檢查部位
  • 切片檢查材料分析
  • 癌症的徵兆:液態切片技術
  • 癌症治療通訊協定的變化
  • 產業結構
  • 主要的液態切片企業簡介

第3章 市場趨勢

  • 促進成長要素
  • 阻礙成長要素
  • 測量化和自動化
  • 診斷技術的發展

第4章 液態切片的近幾年發展

  • 近幾年的發展
  • Illumina:透過活體組織切片使早期發現癌症成為可能而成立新公司、GRAIL
  • ASCO:液態切片的研究人員展現的進步、持續中的課題 等

第5章 各國市場:北美

  • 美國
    • 肺癌檢驗:檢驗數、價格、收益
    • 乳癌:檢驗數、價格、收益
    • 大腸癌:檢驗數、價格、收益
    • 前列腺癌:檢驗數、價格、收益
    • 其他癌症檢驗:檢驗數、價格、收益
    • 液態切片總數:檢驗數、價格、收益
  • 加拿大

第6章 各國市場:歐洲

  • 法國
  • 德國
  • 英國
  • 西班牙
  • 義大利
  • 俄羅斯
  • 其他的歐洲、FSU (舊蘇聯)

第7章 各國市場:亞太地區

  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 其他

第8章 各國市場:南美、非洲、中東

  • 巴西
  • 墨西哥
  • 南美的其他地區
  • 非洲、中東

第9章 全球市場:摘要

  • 全球

第10章 潛在的市場機會的規模

  • 癌症篩檢,各國:肺癌,乳癌及大腸癌
  • 癌症篩檢,各國:前列腺癌、其他癌症及所有癌症
  • 潛在市場規模:癌症診斷
  • 潛在市場規模:癌症管理

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Overview:

The Diagnostic, Monitoring and Screening Test opportunities are explored.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.

Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers.

What is the size of the huge screening opportunity?

They are all listed in Chapter 10.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell is a member of The American Association for Clinical Chemistry.

Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Introduction and Market Definition

  • 1.1. What is Liquid Biopsy?
  • 1.2. The Genetics Revolution
  • 1.3. Market Definition
    • 1.3.1. Volumes
    • 1.3.2. Prices
    • 1.3.3. Revenue Market Size
  • 1.4. Methodology
    • 1.4.1. Authors
    • 1.4.2. Sources
  • 1.5. Liquid Biopsy and Clinical Laboratory Testing - Spending Perspective
    • 1.5.1. U.S. Medicare Expenditures for Clinical Testing

2. Market Overview

  • 2.1. Market Participants
    • 2.1.1. Academic Research Lab
    • 2.1.2. Diagnostic Test Developer
    • 2.1.3. Genomic Instrumentation Supplier
      • 2.1.3.1. Cell Separation and Viewing Instrumentation Supplier
    • 2.1.4. Pharmaceutical/Reagent Supplier
    • 2.1.5. Independent Testing Lab
    • 2.1.6. Public National/regional lab
    • 2.1.7. Hospital lab
    • 2.1.8. Physician Lab
    • 2.1.9. Audit Body
    • 2.1.10. Certification Body
  • 2.2. Conditions Identified with Biopsies
    • 2.2.1. Cancer
    • 2.2.2. Precancerous conditions
    • 2.2.3. Inflammatory condiditons
  • 2.3. Biopsy Sites
  • 2.4. Analysis of Biopsied Material
  • 2.5. Evidence of Cancer - Liquid Biopsy Technology
    • 2.5.1. Liquid Biopsy Technology Overview
    • 2.5.2. Circulating Tumor Cells
      • 2.5.2.1. Types of CTCs
      • 2.5.2.2. CellSearch Detection Method
      • 2.5.2.3. Epic Sciences Detection Method
      • 2.5.2.4. Maintrac Detection Method
      • 2.5.2.5. Other Methods
    • 2.5.3. Circulating Tumor DNA
    • 2.5.4. Exosomes and Micro Vesicles
  • 2.6. Changing the Cancer Treatment Protocol
    • 2.6.1. Issues and Limitations to Liquid Biopsy Adoption
    • 2.6.2. The Cancer Screening Market Opportunity
      • 2.6.2.1. GRAIL - Exploiting the Screening Opportunity
    • 2.6.3. Cancer Management
      • 2.6.3.1. Risk Assessment Role In Cancer Management
      • 2.6.3.2. Therapy Assessment Role In Cancer Management
      • 2.6.3.3. Disease Monitoring Role In Cancer Management
    • 2.6.4. Phases of Adoption - Outlook for Usage
    • 2.6.5. The Promise of Liquid Biopsy
  • 2.7. Industry Structure
    • 2.7.1. Hospital Testing Share
    • 2.7.2. Economies of Scale
      • 2.7.2.1. Hospital vs. Central Lab
    • 2.7.3. Physician Office Lab's
    • 2.7.4. Physician's and POCT
  • 2.8. Profiles of Key Liquid Biopsy Companies
    • 2.8.1. AdnaGen (now Qiagen)
    • 2.8.2. Agena Bioscience
    • 2.8.3. Angle plc
    • 2.8.4. ApoCell
    • 2.8.5. Biocept
    • 2.8.6. BioFluidica
    • 2.8.7. Bio-Rad Laboratories
    • 2.8.8. Boreal Genomics
    • 2.8.10. Chronix Biomedical
    • 2.8.11. Clearbridge BioMedics
    • 2.8.12. Cynvenio
    • 2.8.13. Cytolumina Technologies Corp
    • 2.8.14. CytoTrack
    • 2.8.15. Diagnologix LLC
    • 2.8.16. Epic Sciences
    • 2.8.17. Exosome Diagnostics
    • 2.8.18. Exosome Sciences
    • 2.8.19. Fluidigm Corp
    • 2.8.20. Fluxion Biosciences
    • 2.8.21. Genomic Health
    • 2.8.39. GRAIL
    • 2.8.22. Guardant Health
    • 2.8.23. HansaBiomed
    • 2.8.23. Horizon Discovery
    • 2.8.24. iCellate
    • 2.8.25. Illumina
    • 2.8.26. Inivata
    • 2.8.27. Janssen Diagnostics
    • 2.8.28. Molecular MD
    • 2.8.29. Myriad Genetics
    • 2.8.30. Natera
    • 2.8.31. New Oncology
    • 2.8.32. Personal Genome Diagnostics
    • 2.8.33. RainDance Technologies
    • 2.8.34. Rarecells SAS
    • 2.8.35. Silicon Biosystems
    • 2.8.36. Sysmex Inostics
    • 2.8.37. SRI International
    • 2.8.38. Trovagene

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. Non Invasive Game Changer
    • 3.1.2. Lower Cost
    • 3.1.3. Greater Accuracy.
    • 3.1.4. Wide Range of Potential Uses
    • 3.1.5. Aging Population
  • 3.2. Factors Limiting Growth
    • 3.2.1. Lower prices
    • 3.2.2. Lack of Standards.
    • 3.2.3. Protocol Resistance.
    • 3.2.4. Initial Adoption Has No Cost Savings
  • 3.3. Instrumentation and Automation
    • 3.3.1. Instruments Key to Market Share
    • 3.3.2. Bioinformatics Plays a Role.
  • 3.4. Diagnostic Technology Development
    • 3.4.1. Next Generation Sequencing Fuels a Revolution
    • 3.4.2. Impact of NGS on pricing
    • 3.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4. CGES Testing, A Brave New World
    • 3.4.5. Biochips/Giant magneto resistance based assay

4. Liquid Biopsy Recent Developments

  • 4.1. Recent Developments - Importance and How to Use This Section
    • 4.1.1. Importance of These Developments
    • 4.1.2. How to Use This Section
  • 4.2. Illumina Forms GRAIL to Enable Early Cancer Detection via Liquid Biopsy
  • 4.3. ASCO: Researchers Present Advances, Ongoing Challenges in Liquid Biopsy
  • 4.4. Guardant Health, SWOG Partner on Prospective NSCLC Liquid Biopsy Study
  • 4.5. Qiagen Expands CDx Deal with Tokai; Acquires CTC Assets from AdnaGen
  • 4.6. Biodesix's GeneStrat Liquid Biopsy Lung Cancer Test
  • 4.7. Baylor, TGen Collaborate on Personalized Cancer Treatment Options
  • 4.8. Liquid Biopsy Firm Resolution Bio Gets CLIA Certification for Lab
  • 4.9. Broad Institute Lands $10M Gift to Study Cancer Drug Resistance
  • 4.10. Biocept Q1 Revenues Rise With Test Volume Growth
  • 4.11. CRUK Manchester Institute Joins European Consortium Validating Blood-based Cancer Biomarkers
  • 4.12. New Oncology Closes Financing Round to Promote Genetic Testing from Blood
  • 4.13. Cynvenio to present new clinical data
  • 4.14. EKF, Angle Collaborate for Liquid Biopsy Development
  • 4.15. Trovagene Collaborates with UCSD for EGFR Monitoring in Lung Cancer
  • 4.16. AstraZeneca Initiates CDx Partnerships with Roche, Qiagen
  • 4.17. Horizon, LGC Awarded Research Grant for Cancer Diagnostics
  • 4.18. Merck Serono and Sysmex Inostics Announce Testing Center
  • 4.19. Agena Bioscience Launches Smaller Format MassArray
  • 4.20. Personal Genome Diagnostics Aims for FDA Clearance
  • 4.21. HTG Molecular Diagnostics Files for IPO of up to $60M
  • 4.22. Genomic Health Reports 5 Percent Revenue Growth in Third Quarter
  • 4.23. Biocept, Rosetta Genomics Partner to Profile microRNAs from CTCs
  • 4.24. Inivata Raises $6.6M to Develop ctDNA Assays
  • 4.25. Epic Sciences Raises $30M in Private Financing
  • 4.26. New Release in Line of Liquid Biopsy CLIA Tests
  • 4.27. Collaborators Publish Data on Resolution Bio Liquid Biopsy Test
  • 4.27. Trovagene's Urine-Based Liquid Biopsy Platform Demonstrated in Field
  • 4.28. FDA Sends Pathway Genomics Untitled Letter Over Liquid Biopsy Test
  • 4.29. DNA in blood can track cancer development, response in real time
  • 4.30. Cynvenio Clinical Trial Supports Multi-Template Liquid Biopsy Sequencing
  • 4.31. Startup AccuraGen to Tap China Liquid Biopsy Market With 61-Gene Assay
  • 4.32. Sysmex Corporation and Clearbridge BioMedics to Jointly Develop New Liquid Biopsy System
  • 4.33. MDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States
  • 4.34. GATC Biotech's Liquid Biopsy Testing Takes Cost Lead
  • 4.35. Liquid Biotech USA, Inc. Announces Completion of Clinical Study
  • 4.36. Liquid biopsies more effective in some cases than tissue biopsies
  • 4.37. Cancer Genetics, Inc. and ApoCell Announce Partnership for Rare Cell Capture and Detection
  • 4.38. Exosome Diagnostics Launches Liquid Biopsy Test to Rule Out High-Grade Prostate Cancer
  • 4.39. Liquid Biopsy Tests Partially Validated
  • 4.40. FDA Approves Liquid Biopsy
  • 4.41. Liquid Biopsy Predicts Colon Cancer Recurrence
  • 4.42. WaveSense Receives CE-IVD Mark for Cell Enrichment Platform
  • 4.43. For Liquid Biopsy, Size Matters
  • 4.44. Liquid biopsy startup Freenome lands $5.5 million led by Andreessen Horowitz
  • 4.45. Trovagene, USC Collaborate on Deployment of Urine-Based Liquid Biopsy Test
  • 4.46. Circulogene liquid biopsy detects new tumor mass earlier than current imaging methods

5. Country Market Sizes - North America

  • 5.1. United States of America
    • 5.1.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 5.1.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 5.1.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 5.1.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 5.1.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 5.1.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 5.2. Canada
    • 5.2.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 5.2.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 5.2.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 5.2.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 5.2.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 5.2.6. All Liquid Biopsy Total - Volumes, Prices, Revenues

6. Country Markets - Europe

  • 6.1. France
    • 6.1.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.1.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.1.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.1.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.1.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.1.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.2. Germany
    • 6.2.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.2.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.2.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.2.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.2.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.2.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.3. United Kingdom
    • 6.3.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.3.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.3.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.3.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.3.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.3.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.4. Spain
    • 6.4.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.4.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.4.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.4.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.4.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.4.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.5. Italy
    • 6.5.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.5.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.5.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.5.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.5.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.5.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.6. Russia
    • 6.6.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.6.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.6.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.6.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.6.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.6.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 6.7. Remainder of Europe and Former Soviet Union
    • 6.7.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 6.7.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 6.7.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 6.7.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 6.7.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 6.7.6. All Liquid Biopsy Total - Volumes, Prices, Revenues

7. Country Markets - Asia Pacific

  • 7.1. China
    • 7.1.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.1.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.1.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.1.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.1.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 7.1.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.2. Japan
    • 7.2.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.2.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.2.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.2.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.2.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 7.2.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.3. South Korea
    • 7.3.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.3.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.3.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.3.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.3.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 7.3.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.4. India
    • 7.4.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.4.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.4.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.4.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.4.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 7.4.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.5. Australia
    • 7.5.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.5.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.5.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.5.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.5.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 7.5.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 7.6. Rest of Asia Pacific
    • 7.6.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 7.6.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 7.6.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 7.6.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 7.6.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 7.6.6. All Liquid Biopsy Total - Volumes, Prices, Revenues

8. Country Markets - Latin America, Africa & The Middle East

  • 8.1. Brazil
    • 8.1.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.1.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.1.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.1.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.1.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 8.1.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 8.2. Mexico
    • 8.2.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.2.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.2.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.2.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.2.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 8.2.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 8.3. Rest of Latin America
    • 8.3.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.3.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.3.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.3.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.3.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 8.3.6. All Liquid Biopsy Total - Volumes, Prices, Revenues
  • 8.4. Africa and The Middle East
    • 8.4.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 8.4.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 8.4.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 8.4.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 8.4.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 8.4.6. All Liquid Biopsy Total - Volumes, Prices, Revenues

9. Global Market Summary

  • 9.1. Global
    • 9.1.1. Lung Cancer Testing - Volumes, Prices, Revenues
    • 9.1.2. Breast Cancer Testing - Volumes, Prices, Revenues
    • 9.1.3. Colorectal Cancer Testing - Volumes, Prices, Revenues
    • 9.1.4. Prostate Cancer Testing - Volumes, Prices, Revenues
    • 9.1.5. Other Cancer Testing - Volumes, Prices, Revenues
    • 9.1.6. All Liquid Biopsy Total - Volumes, Prices, Revenues

10. Potential Market Opportunity Sizes

  • 10.1. Cancer Screening by Country: Lung, Breast & Colorectal
  • 10.2. Cancer Screening by Country: Prostate, Other Cancer & All Cancer
  • 10.3. Potential Market Size - Cancer Diagnosis
  • 10.4. Potential Market Size - Cancer Management

Appendices

  • I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule - National Limit and Midpoint
  • II. FDA Approved Human Genetic Tests
  • III. FDA Approved Pharmacogenomics Tests

Table of Tables

  • Table 1: Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 2: Market Players by Type
  • Table 3: Biopsy Sites
  • Table 4: Advantages of Liquid Biopsy in Screening Market
  • Table 5: Five Factors Driving Growth
  • Table 6: Four Factors Limiting Growth
  • Table 7: Key Diagnostic Laboratory Technology Trends
  • Table 8: Next Generation Sequencing Technologies - Speed and Cost
  • Table 9: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 10: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 11: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 12: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 13: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 14: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 15: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 16: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 17: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 18: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 19: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 20: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 21: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 22: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 23: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 24: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 25: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 26: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 27: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 28: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 29: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 30: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 31: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 32: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 33: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 34: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 35: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 36: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 37: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 38: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 39: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 40: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 41: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 42: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 43: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 44: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 45: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 46: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 47: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 48: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 49: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 50: All Liquid Biopsy Testing - Volume, Price and Revenue Forecast
  • Table 51: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 52: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 53: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 54: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 55: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 56: All Liquid Biopsy - Volume Price and Revenue Forecast
  • Table 57: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 58: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 59: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 60: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 61: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 62: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 63: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 64: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 65: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 66: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 67: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 68: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 69: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 70: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 71: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 72: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 73: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 74: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 75: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 76: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 77: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 78: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 79: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 80: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 81: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 82: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 83: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 84: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 85: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 86: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 87: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 88: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 89: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 90: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 91: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 92: All Liquid Biopsy Testing - Volume, Price and Revenue Forecast
  • Table 93: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 94: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 95: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 96: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 97: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 98: All Liquid Biopsy - Volume Price and Revenue Forecast
  • Table 99: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 100: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 101: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 102: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 103: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 104: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 105: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 106: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 107: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 108: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 109: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 110: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 111: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 112: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 113: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 114: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 115: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 116: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 117: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 118: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 119: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 120: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 121: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 122: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 123: Lung Cancer Testing - Volume Price and Revenue Forecast
  • Table 124: Breast Cancer Testing - Volume Price and Revenue Forecast
  • Table 125: Colorectal Cancer Testing - Volume Price and Revenue Forecast
  • Table 126: Prostate Cancer Testing - Volume Price and Revenue Forecast
  • Table 127: Other Cancer Testing - Volume Price and Revenue Forecast
  • Table 128: All Liquid Biopsy Testing - Volume Price and Revenue Forecast
  • Table 129: Potential Screening Market: Lung, Breast & Colorectal
  • Table 130: Potential Screening Market: Prostate, Other & All
  • Table 131: Potential Cancer Diagnosis Market Size
  • Table 132: Potential Cancer Management Market Size
  • Table 133: 2015 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 2: Comparison of Liquid Biopsy Classes
  • Figure 3: Characteristics of Different Vesicle Types
  • Figure 4: Percentage of World Population Over 65
Back to Top